Matthew Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matthew Campbell has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alex Preston
Epigenetics Discovery Performance Unit, GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, U.K.
1 shared publication Alexander N. Phillipou
GlaxoSmithKline, Med Design Med Sci & Technol, Stevenage SG1 2NY, Herts, England
1 shared publicationCarl Haslam
Platform Technology and Sciences, Medicines Research Centre, GlaxoSmithKline R&D , Stevenage SG1 2NY, U.K.
1 shared publicationCassie Messenger
GlaxoSmithKline, Med Design Med Sci & Technol, Stevenage SG1 2NY, Herts, England
1 shared publicationCharles S. Lay
Univ Nottingham, Sch Life Sci, Div Physiol Pharmacol & Neurosci, Nottingham NG7 2UH, England
1 shared publicationCharlotte E. Carver
GlaxoSmithKline, Med Design Med Sci & Technol, Stevenage SG1 2NY, Herts, England
1 shared publication
Latest Publications
- 1 February 2022
- Published by Elsevier in Cell Chemical Biology
- Vol. 29 (2) , 287-299.e8
Development of an intracellular quantitative assay to measure compound binding kinetics
- 1 February 2022
- Published by Elsevier in Cell Chemical Biology
- Vol. 29 (2) , 287-299.e8
Development of an intracellular quantitative assay to measure compound binding kinetics
- 15 January 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (4) , 1370-1387
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives
Following the discovery of cell penetrant pyridine-4-carboxylate inhibitors of the KDM4 (JMJD2) and KDM5 (JARID1) families of histone lysine demethylases (e.g., 1), further optimization led to the identification of non-carboxylate inhibitors derived from pyrido[3,4-d]pyrimidin-4(3H)-one. A number of exemplars such as compound 41 possess interesting activity profiles in KDM4C and KDM5C biochemical and target-specific, cellular mechanistic assays.
- 15 January 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (4) , 1370-1387
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives
Following the discovery of cell penetrant pyridine-4-carboxylate inhibitors of the KDM4 (JMJD2) and KDM5 (JARID1) families of histone lysine demethylases (e.g., 1), further optimization led to the identification of non-carboxylate inhibitors derived from pyrido[3,4-d]pyrimidin-4(3H)-one. A number of exemplars such as compound 41 possess interesting activity profiles in KDM4C and KDM5C biochemical and target-specific, cellular mechanistic assays.